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Abstract: The definition of peri-prosthetic joint infection (PJI) has a strong impact on the diagnostic
pathway and on treatment decisions. In the last decade, at least five different definitions of
peri-prosthetic joint infection (PJI) have been proposed, each one with intrinsic limitations. In order to
move a step forward, the World Association against Infection in Orthopedics and Trauma (W.A.I.O.T.)
has studied a possible alternative solution, based on three parameters: 1. the relative ability of each
diagnostic test or procedure to Rule OUT and/or to Rule IN a PJI; 2. the clinical presentation; 3.
the distinction between pre/intra-operative findings and post-operative confirmation. According to
the WAIOT definition, any positive Rule IN test (a test with a specificity > 90%) scores +1, while a
negative Rule OUT test (a test with a sensitivity > 90%) scores −1. When a minimum of two Rule IN
and two Rule OUT tests are performed in a given patient, the balance between positive and negative
tests, interpreted in the light of the clinical presentation and of the post-operative findings, allows to
identify five different conditions: High-Grade PJI (score ≥ 1), Low-Grade PJI (≥0), Biofilm-related
implant malfunction, Contamination and No infection (all scoring < 0). The proposed definition
leaves the physician free to choose among different tests with similar sensitivity or specificity, on the
basis of medical, logistical and economic considerations, while novel tests or diagnostic procedures
can be implemented in the definition at any time, provided that they meet the required sensitivity
and/or specificity thresholds. Key procedures to confirm or to exclude the diagnosis of PJI remain
post-operative histological and microbiological analysis; in this regard, given the biofilm-related
nature of PJI, microbiological investigations should be conducted with proper sampling, closed
transport systems, antibiofilm processing of tissue samples and explanted biomaterials, and prolonged
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cultures. The proposed WAIOT definition is the result of an international, multidisciplinary effort.
Next step will be a large scale, multicenter clinical validation trial.
Keywords: diagnosis; infection; joint prosthesis; PJI; definition; criteria; WAIOT
1. Introduction
“There is no single accepted set of diagnostic criteria for PJI. Various definitions have been
proposed; however, none have been widely adopted. Furthermore, some of these definitions disagree
with each other ( . . . )”. Based on these considerations, the workgroup of Musculoskeletal Infection
Society (MSIS) declared in 2011 “the intention ( . . . ) to have a “gold standard” definition for PJI” and
proposed a set of major and minor criteria to define a peri-prosthetic joint infection (PJI) [1].
From a scientific point of view, the lack of a common definition of a clinical condition is a source
of bias when comparing the results from different studies, weakening the power of systematic reviews
and meta-analysis [2]. On the other hand, from a clinical perspective, defining a PJI plays a strategic
role to decide the tests that need to be performed in a given patient; consequently, the definition of
PJI is driving treatment and prognosis and has a strong impact on epidemiological, social, economic
and medico-legal evaluations [3]. As a matter of fact, the lack of a shared PJI definition is limiting our
ability to standardize the diagnostic pathway and the treatment choice.
However, in spite of the MSIS declaration and the recognized need for a univocal and shared
definition of PJI, since 2011 at least four more formulas have been published, all from highly respected
scientific institutions, including the Infectious Disease Society of America (IDSA) [4], two International
Consensus Meetings [5–7] and, more recently, the European Bone and Joint Infection Society (EBJIS) [8].
To sum it up, in less than a decade at least five different definitions of PJI have been released,
proposing a wide and heterogeneous set of criteria, scoring systems and reference values (Table 1).
The difficulty of finding “a gold standard” relies on many factors. Peri-prosthetic infection has a wide
range of clinical presentations, from the acute, high-grade to the subclinical low-grade one [8–10];
moreover, novel markers and diagnostic tools are continuously discovered [11–13], making any
definition criteria quickly obsolete. Furthermore, in the lack of an accepted benchmark towards which
the definition itself can be validated, the professional and scientific background of the panel of experts
may bias their choice of the definition criteria. As a result, in spite of the several attempts, current
definitions still appear limited in their ability to distinguish the different clinical presentations and even
the most recent and complex scores may result as “Inconclusive” [6]. Moreover, imaging techniques,
with a proven diagnostic accuracy, are not included [14], while laboratory tests with similar sensitivity
or specificity cannot be used alternatively, thus restricting the choice for physicians that operate in a
scarce resources environment and prompting the adoption of novel, often more expensive, biomarkers.
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Table 1. Comparison of the diagnostic criteria, adopted in five peri-prosthetic joint infection (PJI) definitions, published from 2011 to 2018.
Definition Source MSIS 2011 [1] IDSA 2013 [4] ICM 2013 [5] ICM 2018 [7] Proposed EBJIS 2018 [8]
Scoring system
1 of the 2 Major Criteria
OR
≥4 of 6 Minor Criteria *
≥1 Positive Criteria *
1 of the 2 Major Criteria
OR
≥3 of 5 Minor Criteria *
1 of the 2 Major Criteria
OR
Minor criteria scoring ≥6 Infected
3–5 Possibly infected
(“Consider further molecular diagnostics
such as next-generation sequencing”)
<3 Not infected *
≥1 Positive Criteria
* “PJI may be present if fewer than four
of these criteria are met”
* “The presence of PJI is possible even if
the above criteria are not met ( . . . )”
* “PJI may be present without
meeting these criteria, ( . . . ).”
* “Proceed with caution in: adverse local
tissue reaction, crystal deposition disease,
slow growing organisms”
Criteria Major:
1. Sinus tract communicating with
the prosthesis;
2. A pathogen is isolated by culture
from at least two separate tissue or
fluid samples obtained from the
affected prosthetic joint
Minor:
(a) Elevated ESR (>30 mm/hr) and
CRP (>10 mg/L) concentration
(b) Elevated synovial leukocyte count
(c) Elevated PMN%
(d) Purulence in the affected joint
(e) Isolation of a microorganism in one
culture of periprosthetic tissue
or fluid
(f) Greater than five neutrophils per
high-power field in five
high-power fields observed from
histologic analysis of periprosthetic
tissue at x400 magnification
1. Sinus tract communicating with
the prosthesis
2. Purulence without other etiology
surrounding the prosthesis
3. Acute inflammation seen on
histopathological examination of
the periprosthetic tissue
4. ≥ 2 intraoperative cultures or
combination of preoperative
aspiration and intraoperative
cultures yielding an
indistinguishable organism [the
growth of a virulent microorganism
(e.g., Staphylococcus aureus) in a
single specimen of a tissue biopsy
or synovial fluid is also considered
as indicative of a PJI]
Major
1. A sinus tract communicating
with the joint
2. Two positive periprosthetic
cultures with phenotypically
identical organisms,
Minor:
(a) Elevated ESR (>30 mm/hr) and
CRP (>100 mg/L for acute
infections; >10 mg/L for
chronic infections)
(b) Elevated synovial fluid WBC
count (>10,000 cells/mL for
acute infections; >3,000
cells/mL for chronic infections)
or ++ change on leukocyte
esterase test strip
(c) Elevated PMN% (>90% for
acute infections; >80% for
chronic infections)
(d) Positive histological analysis of
periprosthetic tissue (> 5
neutrophils per high-power
field in five high-power fields
observed on periprosthetic
tissue at x400 magnification)
(e) A single positive culture
Major:
1. Sinus tract with evidence of
communication to the joint or
visualization of the prosthesis
2. Two positive growths of the same
organism using standard
culture methods
Minor:
(a) Elevated CRP (>100 mg/L for acute
infections; >10 mg/L for chronic
infections) or D-Dimer (unknown
threshold for acute infection; >860
ug/L for chronic infection) (score 2)
(b) Elevated ESR (no role for acute
infections; >30 mm/hr for chronic
infections) (score 1)
(c) Elevated synovial WBC count
(>10,000 cells/mL for acute
infections; >3,000 cells/mL for
chronic infections) OR Leukocyte
Esterase (++ for acute and chronic
infections) OR Positive
alpha-defensin (score 3)
(d) Elevated synovial PMN% (>90%
for acute infections; >70% for
chronic infections) (score 2)
(e) Single positive culture (score 2)
(f) Positive histology (score 3)
(g) Positive intraoperative purulence
(score 3)
1. Purulence around the
prosthesis or sinus tract
2. Increase synovial fluid
leukocyte count (>2,000
cells/mL or >70 % granulocytes)
3. Positive histopathology
4. Confirmatory microbial growth
in synovial fluid, periprosthetic
tissue, or sonication culture
(“Confirmatory microbial growth in
periprosthetic tissue: if positive in ≥1
specimen in highly virulent
organisms or ≥ 2 in low virulent
pathogens; sonication culture
considered positive if >50
colony-forming units/mL of
sonication fluid.”)
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In this panorama, the WAIOT multidisciplinary Study Group on Bone and Joint Infection
Definitions is proposing a novel approach to PJI definition, based on the relative ability of the available
tests to confirm (rule in) or to exclude (rule out) a peri-prosthetic infection, applied to the various
clinical presentations, with post-operative validation.
2. Pre- and Intra-Operative Rule IN and Rule OUT Test: Definition and Selection
The accuracy of any diagnostic test with continuous results, as the majority of those used for
peri-prosthetic infection diagnosis are, depends on its cut-off value [15]. Choosing an appropriate
cut-off value is then of paramount importance in using a test effectively.
Several criteria, mostly based on Receiver Operating Characteristic (ROC) curve analysis, have so
far been proposed for choosing the most appropriate cut-off value [16]. Each point on a ROC curve
corresponds to a cut-off value and is associated with a test True Positive rate (Sensitivity, Se) and a
False Positive rate (1-Specificity, 1-Sp). Choosing the cut-off point for clinical application thus requires
a compromise between desired Se and Sp. If there is no preference between Se and Sp, a commonly
followed approach is to maximize both indices. Even with this procedure, however, any cut-off value
that will be finally chosen will inevitably be associated with a better sensitivity or specificity. This fact
should be taken into consideration when using a given test in the clinical setting.
For example, if we consider the serum C-Reactive Protein (C-RP) levels at a cut-off value of 10 mg/L,
according to Ghanem and co-workers [17] this marker has a sensitivity of 91.1% (95% confidence
interval [CI]: 85–95) and a specificity of only 76.6% (72–81) to diagnose a PJI. Hence, a negative C-RP
test is quite reliable at excluding an infection, while a positive C-RP is not so accurate to confirm the
disease. According to these findings, C-RP is then to be considered a good rule OUT test, but only a
moderately reliable Rule IN test.
At the opposite, serum procalcitonin (PC), according to a recent meta-analysis [18], features
only 58% (95% CI, 31–81) sensitivity but 95% specificity (95% CI, 63–100). On this basis, PC is to be
considered a good Rule IN test, but not a useful Rule OUT examination.
For the purpose of the proposed WAIOT definition of PJI, all the tests and diagnostic procedures,
that can be performed pre- or intra-operatively and that have been shown to have a sensitivity >
90%, are included as “Rule OUT” tests, while those with a specificity > 90% are considered “Rule IN”
tests. If a test does show a sensitivity AND a specificity > 90%, it will be included both as a “Rule
OUT” and “Rule IN” test. In order to select the Rule OUT and Rule IN tests, a literature search has
been conducted by the WAIOT Study Group on the relevant search engines in order to assess the
relative sensitivity and specificity of various tests and procedures commonly used to diagnose a PJI.
In particular, we searched for all studies (retrospective, prospective, or randomized controlled trials)
reporting on diagnosis of peri-prosthetic joint infection in MEDLINE, EMBASE, Web of Science, and
Cochrane databases from inception up to December 2018. The search strategy used a combination of
key words related to PJI with focus un diagnosis, serum and synovial markers, histology, imaging and
microbiological techniques. Only papers in English were reviewed. We complemented the search by
manually scanning reference lists of identified articles and review articles for relevant publications
missed by the original search.
The selection has then been made through a progressively higher scientific evidence criteria,
choosing first the cut-off and sensitivity/specificity values emerging from meta-analysis or systematic
reviews and, if these were not available, the values reported from studies with the largest patients’
populations. Tests validated in cohorts of patients of less than 50 patients were excluded, while
purulence, draining sinus and implant exposure were considered highly specific, even in the absence
of a clinical trial to support this assumption. The results are reported in Table 2.
It is worth noting that the proposed definition of PJI allows one to add novel tests and markers of PJI
at any time, provided that they meet the sensitivity/specificity threshold requirements mentioned above.
To define a PJI, any negative “Rule OUT” tests is scored −1, while any positive “Rule IN” test is
scored +1. The score of a positive Rule OUT test or that of a negative Rule IN test is rated 0.
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Table 2. Pre- and intra-operative tests, classified according to their sensitivity and specificity and hence
their ability to exclude (“Rule OUT”) or to confirm (“Rule IN”) a PJI. In parenthesis, the reference
cut-off value considered here.
Rule OUT Tests (Sensitivity > 90%)
EACH NEGATIVE TEST Scores −1
(Positive Rule OUT Tests Score 0)
Serum ESR (>30 mm/h) [17]CRP (>10 mg/L) [17]
Synovial fluid
WBC (>1,500/µL) [19]
LE (++) [20,21]
Alpha-Defensin immunoassay (>5.2 mg/L) [22,23]
Imaging Tc99 bone scan [24]
Rule IN Tests (Specificity > 90%)
EACH POSITIVE TEST Scores +1
(Negative Rule IN Tests Score 0)
Clinical examination Purulence or draining sinus or exposed joint prosthesis
Serum
IL-6 (>10 pg/mL) [18]
PC (>0.5 ng/mL) [18]
D-Dimer (>850 ng/mL) [25]
Synovial fluid
Cultural examination [26]
WBC (>3,000/mL) [19,27]
LE (++) [20,21]
Alpha-Defensin immunoassay (>5.2 mg/L) [22,23] or lateral flow test [28]
Imaging Combined leukocyte and bone marrow scintigraphy [24]
Histology Frozen section (5 neutrophils in at least 3 HPFs) [29]
Abbreviations: ESR: erythrocyte sedimentation rate; CRP: C-Reactive Protein; IL-6: Interleukin-6; WBC: White
blood cell count; PC: Procalcitonin; LE: Leukocyte esterase strip (++); HPFs: high power fields (×400).
The rationale of this scoring modality relies on two basic observations. The first is that, by
definition, two tests with similar sensitivity are equally effective at excluding a given condition.
This observation grounds the basis to score all the negative Rule OUT tests the same (−1 point); a
similar rationale does apply for scoring with the same value all the positive Rule IN tests.
The second observation is that, given the fact that the same threshold for sensitivity and specificity
(>90%) was chosen to include a test as a Rule OUT or a Rule IN test, we may assume that the relative
ability of a positive Rule IN test to confirm the infection and that of a negative Rule OUT test to exclude
the infection are similar. This is why each negative Rule OUT tests score is scored −1 and each positive
Rule IN test is rated exactly +1
3. Post-Operative, Confirmative Tests
Post-operative findings, including histology and microbiological analysis of tissue samples and
of explanted biomaterials, may only become available, with current technologies, days after surgery.
Even if these tests may not be used to drive surgical decision, their importance to confirm pre- and
intra-operative findings is obvious from a clinical, epidemiological, research and medico-legal points
of view.
Histology is important not only to confirm a possible PJI [30,31], but also to identify other
reasons for implant failure, including the presence of metallosis or immunological reactions, as well
as tumors [32–34]. With currently used thresholds, if correctly performed [29], histology is to be
considered a highly specific investigation [35].
Similarly, microbiological analysis on tissue samples and on explanted biomaterials is mandatory
in all cases of suspicion of infection. It not only provides a confirmation of the diagnosis, but also
drives the antibiotic treatment.
Given the key confirmatory role played by microbiology in the present PJI definition,
microbiological analysis should follow some basic rules, known to improve the results. The adherence
to a correct sampling policy is strategic to reduce the occurrence of both false positive and false negative
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cultural examinations. In particular, concerning the latter, the presence of the biofilms on both the
surface of the infected biomaterials and of contaminated tissues and the fact that bacteria may persist
even in fluids as aggregates of biofilm-embedded microorganisms [36]
Concerning sampling, from 3 to 6 tissue samples should be taken, reducing the contamination
risks with specific sampling tray and closed transport systems or blood culture bottles [37,38]; explanted
biomaterials, including the prosthesis, modular parts and bone cement should also be sent for
microbiological examination, using antibiofilm mechanical or chemical processing techniques [39–41].
Finally, cultures should be maintained for at least 14 days, in order to detect slow-growing
microorganisms, while caution should be exerted when interpreting negative cultural examinations in
patients that received antibiotics close or at the time of sampling [42–45].
Considering the importance of pathogen(s) identification and especially the need for identifying
their antibiotic resistance profile, microbiology remains pivotal to confirm a PJI. Molecular assays,
like for example MALDI-TOF mass spectrometry, Next Generation Sequencing (NGS) and other
metagenomic procedures, that have been recently developed to provide a quick diagnosis, have not
yet demonstrated their superiority compared to traditional cultural examination, in the clinical setting,
but they may prove a useful tool in the next future [46,47].
4. WAIOT Definition of PJI
According to the proposed definition, a minimum of two “Rule OUT” and two “Rule IN” tests
needs to be performed in any given patient, in order to define the presence of a peri-prosthetic
joint infection.
Regarding the choice of the tests, there is not a fixed prescription and the clinician is left free
to decide, in any given patient, on the basis of clinical, logistical and economic considerations. This
recommendation takes into account the lack of scientific evidence showing a superiority between tests
with similar sensitivity or specificity.
As for the number of the tests, provided that the minimum of two “Rule OUT” and two “Rule
IN” is fulfilled, the physician is left free to perform more investigations, depending on the results
and the clinical suspicion. The level of the clinical suspicion is directly related to the history of the
patient, the clinical presentation and the presence of other conditions, that may explain the signs and
symptoms in that patient. In fact, at variance with the other existing definitions of PJI, in our proposal
the interpretation of the instrumental tests is performed also considering clinical aspects (cf. Table 3).
Table 3. WAIOT proposed definition of peri-prosthetic joint infection (PJI).
No Infection Contamination BIM LG-PJI HG-PJI
Clinical presentation
One or more condition(s), other than
infection, can cause the symptoms or
the reason for reoperation (e.g., wear
debris, metallosis, recurrent dislocation
or joint instability, fracture, malposition,
neuropathic pain)
One or more of the followings:
otherwise “unexplained” pain,
swelling, stiffness
Two or more of the
followings: pain,
swelling, redness,
warmth, functio laesa
# of Positive Rule IN
minus
# of Negative Rule
OUT tests
<0 <0 <0 ≥0 ≥1
Post-operatively
confirmed if
Negative cultural
examination
One pre- or
intra-operative
positive culture,
with negative
histology
Positive cultural examination (preferably with antibiofilm
techniques) and/or positive histology
Abbreviations: WAIOT: World Association against Infection in Orthopedics and Trauma; BIM: Biofilm-related
Implant malfunction; LG-PJI: Low-Grade Peri-Prosthetic Joint Infection; HG-PJI: High-Grade Peri-Prosthetic
Joint Infection.
According to the proposed WAIOT definition, we can distinguish the following five conditions (cf.
Table 3):
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• “High-Grade PJI” (HG-PJI)”. A clinical condition in which two or more signs or symptoms of
local inflammation (pain, swelling, redness, warmth, function laesa) are present. This condition
corresponds to what usually the clinicians call “acute” or “inflammatory” infection [11]; these
patients are defined as affected by PJI if the balance between positive “Rule IN” and negative
“Rule OUT” tests is ≥ 1. Generally, in these patients, only two Rule IN and two Rule OUT tests
are needed, as often the main clinical problem here is not the diagnosis of infection, but the
identification of the pathogen. The condition is considered post-operatively confirmed in case of
positive histological and/or microbiological findings (at least one microbiological sample positive,
microbiological analysis preferably performed with prolonged cultures and antibiofilm technique,
with closed sampling and transport systems);
• “Low-Grade PJI” (LG-PJI). A condition in which, in the lack of acute local inflammatory signs
and in the absence of an alternative explanation for the signs or symptoms, the patient complains
for at least one of the followings: otherwise “unexplained” pain, swelling and/or reduced range of
motion or functional impairment; often this condition is due to slowly growing microorganism(s)
and it may show up several months or even years after surgery. If the balance between positive
“Rule IN” and negative “Rule OUT” tests is ≥ 0 a Low-Grade PJI should be considered. In these
patients often the clinician will prefer to perform additional tests, other than the minimum 2+2.
The condition will be post-operatively proven in case of positive histology and/or if at least one
microbiological sample is positive (microbiological analysis performed with prolonged cultures
and antibiofilm technique, preferably using closed sampling and transport systems);
• “Biofilm-related implant malfunction” (BIM). A condition similar to LG-PJI, but where the
balance between positive “Rule IN” tests and negative “Rule OUT” tests is < 0. In this case
the diagnosis may only be confirmed post-operatively, based on positive histology and/or if at
least one positive microbiological sample (microbiological analysis performed with prolonged
cultures and antibiofilm technique, preferably using closed sampling and transport systems);
often slow-growing microorganisms, like Cutibacterium (previously named Propionibacterium)
acnes, should be expected. It should be noted that patients with BIM may only complain of
moderate pain and/or reduced function, which may be not so severe to necessitate a reoperation,
so a post-operative confirmation of the diagnosis may not be possible in all the cases.
On the average, the estimated incidence of high-grade infection lays in a range of 0.5% to 2.5%
after clean surgery, while low-grade infections and biofilm-related malfunctions probably occur in
approximately 5% to 10%. Beswick et al. [48] in a recent systematic review of prospective studies in
patients undergoing total hip or knee replacement for osteoarthritis, found a proportion of people with
long-term pain of unknown origin ranging from about 7% to 23% after total hip joint replacement and
from 10% to 34% after knee replacement, while other studies have shown that “between 4% and 13%
of patients with preoperative diagnosis of aseptic loosening were infected”, when retrieved implants were
analyzed with genomic identification methods [49]. Furthermore, C. acnes has been identified in recent
years as an occult causative agent of pain after shoulder prosthesis [50].
Contamination is said to occur in a patient with one or more condition, other than infection,
able to motivate the signs or symptoms and the reason for reoperation (e.g., wear debris, recurrent
dislocation or joint instability, fracture, malposition, neuropathic pain, etc.); in this patient the balance
between positive “Rule IN” and negative “Rule OUT” tests is <0, while a microorganism is recovered
from a single synovial fluid or intra-operative sample, but histology is negative.
No infection is here defined as a condition similar to that of “Contamination”, but with negative
cultural examination.
Table 4 outlines some real case examples of patients defined as not infected or, respectively,
affected by a Low- or a High-Grade-PJI.
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Table 4. Real case examples of diagnostic pathways, that can be used to confirm or exclude PJI,
according to the WAIOT proposed definition (n.p.: not performed).
Case 1.
No Infection
Case 2.
Low-Grade PJI
Case 3.
High-Grade PJI
Clinical presentation
Male, 48 years, recurrent
hip arthroplasty
dislocation, undergoing
partial revision 8 months
after joint replacement.
Female, 72 years,
continuous kneepain 12
months after joint
replacement.
Male, 57 years, local
redness, pain, and
swelling, 13 months after
total hip replacement
Pre/Intra-operative Tests
Rule OUT Tests
(If Negative Score −1) Result Score Result Score Result Score
Serum
ESR (>30 mm/h) Positive 0 Positive 0 Positive 0
CRP (>10 mg/L) Negative −1 Negative −1 Positive 0
Synovial
fluid
WBC (>1,500/µL) Negative −1 Negative −1 Positive 0
LE (++) Negative −1 Positive 0 Positive 0
Alpha-Defensin
immunoassay (>5.2 mg/L) n.p. n.p. n.p.
Imaging Tc99 bone scan n.p. Positive 0 n.p.
Rule IN Tests
(If Positive Score +1) Result Score Result Score Result Score
Serum
IL-6 (>10 pg/mL) n.p. Negative 0 n.p.
PC (>0.5 ng/mL) n.p. n.p. n.p.
D-Dimer (>850 ng/mL) n.p. n.p. n.p.
Clinical
examination
Purulence or draining sinus
or exposed joint prosthesis Negative 0 Negative 0 Negative 0
Synovial
fluid
Cultural examination Negative 0 Negative 0 Negative 0
WBC (>3,000/mL) Negative 0 Negative 0 Positive +1
LE (++) Negative 0 Positive +1 Positive +1
Alpha-Defensin
immunoassay (>5.2 mg/L)
or lateral flow test
n.p. n.p. n.p.
Imaging Combined leukocyte andbone marrow scintigraphy n.p. Positive +1 n.p. 0
Histology
Frozen section (5
neutrophils in at least 3
HPFs)
n.p. Negative 0 n.p. 0
TOTAL SCORE −3 0 + 2
Pre-Intra Operative Interpretation No Infection Low-Grade PJI High-Grade PJI
Post-Operative Tests
Histology n.p. Negative Positive
Microbiology Negative Positive Positive
Post-Operative Interpretation No Infection Confirmed LG PJI Confirmed HG PJI Confirmed
5. Discussion
Through a multi-disciplinary and multi-national approach, in an effort to overcome some of the
limitations of the existing score systems, we outlined here a novel approach to define peri-prosthetic
joint infection.
The proposed WAIOT definition of PJI shows the following peculiarities.
First, to the best of our knowledge, this is the only to distinguish between clinical presentations,
including high- and low-grade infections, biofilm-related implant malfunction, contamination and
no infection with a unique scoring system. This distinction takes into account the most recent
understanding of the biofilm-related nature of all the PJIs; [51] in fact, the ability of bacteria to persist
in biofilms and even inside the host’s cells is among the main reasons for PJI clinical presentations
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characterized by no or few inflammatory signs and symptoms with conflicting diagnostic tests’
results [10,52,53].
A second peculiar feature is that the present definition is designed to maximize the use of each
test, taking into account that the available diagnostic procedures may be more effective at confirming
or at excluding a PJI.
A third specific feature is that all the tests that did demonstrate similar sensitivity and specificity
are put on the same level, leaving the choice to the clinician, on the basis of medical, logistical and
economic considerations.
As a matter of fact, current diagnostic pathways are extremely variable and differentiated even
among the centers of excellence around the world [54]. This not only makes the diagnosis less
predictable and homogeneous, but it may also lead to inappropriate use of the available diagnostic tests,
that may be under- or overused. According to a recent trial, the average number of tests performed to
confirm a PJI is 5.8 [55]. The present definition reduces the number of tests needed to define a PJI to a
minimum of two Rule IN and two Rule OUT tests.
Finally, the proposed definition differentiates between a pre-/intra-operative tests and
post-operative histological and microbiological confirmatory findings.
As a practical consequence, the diagnostic pathways can be differentiated, according to the
clinical presentation, allowing some flexibility to the clinician and reserving the most expensive and
sophisticated tests only to those cases in which the diagnosis is particularly challenging. Furthermore,
this approach allows to include novel tests or procedures, provided that they meet the minimum
sensitivity and specificity, without the need for changing the definition structure.
The proposed definition has its own limitations. First, the selection of the tests is based on the
existing literature. The search itself may contain mistakes and be not completely exhaustive; on the
other hand, the cut-off value and the diagnostic accuracy of each test has been investigated according
to different benchmarks and methodologies, causing an intrinsic bias in ours and in any definition
that relies on previous studies. In this regard, it should also be noted that some commonly accepted
tests are only based on semi-quantitative results (e.g., leukocyte esterase strips) or may be subject to
interpretation bias (e.g., nuclear medicine imaging) [56].
The second limitation is the lack of clinical validation. As far as we know, this limit is shared by
all the current definitions [1,4,5,8], except maybe the latest one [7]. In this regard it is worth noting that
the definition criteria and the score, voted at the last Consensus Meeting in Philadelphia in 2018 [7],
do not exactly match the criteria used in the clinical validation study [6]. In particular, synovial fluid
markers were scored differently and also the definition of infection according to the “minor criteria”
was different. Furthermore, the agreement on this definition has been “weak” (68%) [8]. In our opinion,
this lack of consensus was due to several reasons, including, among others, the lack of a reliable
benchmark in the validation study. In fact, in their retrospective analysis, the authors report that
“patients were classified as having a PJI if they met major diagnostic criteria of MSIS”; [6] this means that all
those patients that did not present with a draining sinus or with two positive cultural examinations
were considered as not infected, thus excluding, “by definition” all the patients with a “low-grade
infection” and with difficult-to-diagnose pathogens.
Aware of the challenges posed by clinical validations, our future target is to first retrospectively
apply the proposed WAIOT definition to a large population of patients, comparing the results with
other existing definitions; as a second step a prospective multinational trial aimed at comparing
pre-operative and intra-operative application of the definition with post-operative data is planned.
In conclusion, a simplified definition of PJI, based on the most commonly observed clinical
presentations and on the relative sensitivity and specificity of the available pre/intra-operative tests,
with post-operative confirmation, may be helpful for research applications and for the clinicians willing
to differentiate patients with PJI along with a cost-effective use of the available resources.
From a clinical perspective, this paper highlights the limits and the heterogeneity of the current
definitions of PJI, an observation that needs to be considered in the diagnostic process. Furthermore,
J. Clin. Med. 2019, 8, 650 10 of 13
the proposed new definition allows for the first time to distinguish between high- and low-grade
peri-prosthetic joint infections. This may be helpful in order to raise in the clinicians the legitimate
suspicion that at least some cases of pain of “unknown” origin after joint replacement may, in fact, be
difficult-to-diagnose infections; this, in turn, will hopefully trigger the appropriate type and number of
tests that are needed to come to a correct definition and will consequently will reduce misdiagnosis
and misinterpretation of the data.
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